The short version
- Mechanism: Retatrutide activates GLP‑1 + GIP + glucagon receptors (triple agonist). Tirzepatide activates GLP‑1 + GIP (dual agonist).
- Evidence: Retatrutide phase 2 data in obesity reported about 24% average weight loss at 48 weeks (highest dose, ongoing trend). Tirzepatide’s 72‑week trial in obesity reported ~22.5% average loss at the top dose.
- Availability in Australia: Tirzepatide is approved for type 2 diabetes and an obesity indication is rolling out under the weight‑management brand (supply and eligibility can vary). Retatrutide is investigational only.
- Safety: Both show class‑typical gastrointestinal effects; gallbladder events can occur. Retatrutide’s long‑term profile is still being established.
Mechanisms: triple vs dual agonist
Tirzepatide combines GLP‑1 and GIP receptor agonism. GLP‑1 helps reduce appetite, slow gastric emptying and improve glycaemic control. GIP appears to enhance GLP‑1 effects in certain tissues and may influence adipose and beta‑cell signalling. This synergy is thought to explain the larger weight‑loss effect than older GLP‑1–only medicines.
Retatrutide adds glucagon receptor activity to GLP‑1 and GIP. The rationale is to pair appetite and glycaemic benefits (GLP‑1/GIP) with increased energy expenditure and lipid mobilisation (glucagon). The challenge is balancing glucagon’s metabolic effects to avoid adverse glycaemic swings; dose‑titration and receptor‑balance are central to its design.
Bottom line: dual agonism (tirzepatide) is proven in large phase 3 programs; triple agonism (retatrutide) is promising but remains under investigation.
Weight‑loss results and metabolic outcomes
- Tirzepatide (obesity program): Around 15–22.5% average weight loss at 72 weeks depending on dose, with improvements in waist circumference, blood pressure, lipids and glycaemic markers.
- Retatrutide (phase 2, obesity): Up to ~24% average loss at 48 weeks at the highest studied dose, with curves still trending downward at the data cutoff. Early signals for improvements in cardiometabolic markers were reported.
Important: These figures come from different trials, timeframes and populations. There is no head‑to‑head retatrutide vs tirzepatide study yet, so direct comparisons must be cautious.
For context and deeper dives:
Side effects and safety signals
Shared class effects:
- Gastrointestinal: nausea, vomiting, diarrhoea, constipation—usually dose‑dependent and mitigated by gradual titration.
- Gallbladder: increased risk of gallstones or cholecystitis in rapid weight loss and incretin therapy contexts.
- Pancreatitis: rare but serious; seek urgent care for severe abdominal pain.
- Heart rate: small mean increases reported with incretin drugs.
- Boxed/strong warnings in class: thyroid C‑cell tumours in rodents; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2; avoid in pregnancy.
Retatrutide‑specific notes (investigational): long‑term safety is not yet established. Triple agonism includes glucagon receptor activity, which may influence energy expenditure and hepatic parameters; careful titration has been used in trials.
Tirzepatide‑specific notes: extensive phase 3 data exist across diabetes and obesity programs; safety resembles GLP‑1 class with added GIP activity.
Dosing and delivery
- Tirzepatide: once‑weekly subcutaneous injection via prefilled pens; dose is titrated over several weeks to improve tolerability.
- Retatrutide: once‑weekly subcutaneous injection in clinical trials with structured up‑titration; not commercially available.
Learn more:
Availability and legal status in Australia
- Tirzepatide: approved for type 2 diabetes; an obesity indication is rolling out under the weight‑management brand. Supply, private pricing and PBS coverage can change—confirm with your prescriber and pharmacist.
- Retatrutide: investigational only; access is generally limited to clinical trials. It is not approved for routine prescribing in Australia.
Costs and supply considerations
Tirzepatide costs in Australia vary by dose, brand and pharmacy supply. Private prescriptions for weight management may not be PBS‑subsidised; diabetes indications may have different criteria. Retatrutide has no market price because it is not approved.
Who each option may suit
- Consider tirzepatide if you need an approved, once‑weekly dual agonist with robust phase 3 data and prescriber pathways available now in Australia.
- Consider retatrutide only via clinical trials if you meet inclusion criteria and are comfortable with investigational therapy and additional monitoring requirements.
Alternatives and related comparisons:
Deeper education on each medicine
Frequently asked questions
Retatrutide vs tirzepatide: which works better?
Early data suggest retatrutide may produce greater average weight loss at 48 weeks versus tirzepatide’s 72‑week benchmarks, but there are no direct head‑to‑head trials and retatrutide is not approved. Clinical relevance depends on your health history and goals.
Is retatrutide available in Australia yet?
No. It remains investigational. Access is typically via clinical trials only. See Is Retatrutide Legal in Australia?
Can Australians access tirzepatide for weight management?
Yes—subject to indication, eligibility, clinician assessment, brand availability and current supply. See Buy Tirzepatide Australia and Tirzepatide Prescription Australia.
What side effects should I watch for?
Common GI symptoms (nausea, vomiting, diarrhoea), possible gallbladder events and rare pancreatitis. Contact a clinician if symptoms are severe. Avoid during pregnancy and if you have a personal or family history of MTC/MEN2.
How quickly do results appear?
Most people titrate for several weeks, then see progressive changes over months. See Retatrutide Results Timeline and Tirzepatide Results Timeline.
Are there alternatives if tirzepatide is out of stock?
Clinicians may discuss GLP‑1 options such as semaglutide or other supportive strategies. See Weight Loss Injections Australia and Semaglutide vs Tirzepatide Weight Loss.
Will lifestyle still matter?
Yes. Nutrition, physical activity, sleep and behavioural support enhance outcomes and help maintenance once medication is stopped.
Next steps
- Review eligibility, risks and medicine supply with a qualified prescriber.
- Confirm legal access pathways in Australia.
- Plan titration, side‑effect management and follow‑up care.
Contact form: get help comparing options
Have questions about retatrutide vs tirzepatide, eligibility or access in Australia? Send a message and we’ll connect you with information or a suitable provider pathway.
Important notes
- Information on this page is general and does not replace medical advice.
- Medication availability, indications, PBS status and pricing can change. Always confirm the latest local guidance with a prescriber and pharmacist.
- Retatrutide is investigational; tirzepatide is approved for type 2 diabetes and an obesity indication is rolling out—eligibility varies.